Details
Stereochemistry | ACHIRAL |
Molecular Formula | As2O3 |
Molecular Weight | 197.8414 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][As+](=O)[As]=O
InChI
InChIKey=MOQADKPFYVWPSE-UHFFFAOYSA-N
InChI=1S/As2O3/c3-1-2(4)5
Arsenic trioxide (ATO) is used to treat acute promyelocytic leukemia in people who have not been helped by other types of chemotherapy or whose condition has improved but then worsened following treatment with other types of chemotherapy. Arsenic trioxide acts through activation of Jun N-terminal kinase (JNK), activator protein-1, and inhibition of dual-specificity phosphatases. Although the exact mechanisms under which ATO exerts its therapeutic effect in acute promyelocytic leukemia cancer cells are not well elucidated. It was shown that apoptotic mechanisms involved the induction of phosphatidylserine externalization, caspase-3 activation, and nucleosomal DNA fragmentation. Adverse reactions described are leukocytosis, nausea, vomiting, diarrhea, and abdominal pain, fatigue, edema, hyperglycemia, dyspnea, cough, rash or itching, headaches, and dizziness.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2096667 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12012315 |
|||
Target ID: activator protein-1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12012315 |
|||
Target ID: dual-specificity phosphatases Sources: https://www.ncbi.nlm.nih.gov/pubmed/12012315 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TRISENOX Approved UseAcute promyelocytic leukemia (newly diagnosed) (low-risk disease): Treatment of newly diagnosed low-risk acute promyelocytic leukemia (APL), in combination with tretinoin, in adults whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
Acute promyelocytic leukemia (relapsed or refractory): Remission induction and consolidation treatment of APL in patients who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression Launch Date2000 |
Sample Use Guides
Induction Treatment Schedule: TRISENOX™ should be administered intravenously at a dose of 0.15 mg/kg daily until bone marrow remission. Total induction dose should not exceed 60 doses.
Consolidation Treatment Schedule: Consolidation treatment should begin 3 to 6 weeks after completion of induction therapy. TRISENOX™ should be administered intravenously at a dose of 0.15 mg/kg daily for 25 doses over a period up to 5 weeks.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
TRISENOX (AUTHORIZED: LEUKEMIA, PROMYELOCYTIC, ACUTE)
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
||
|
FDA ORPHAN DRUG |
145701
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
||
|
FDA ORPHAN DRUG |
496415
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
||
|
NCI_THESAURUS |
C1934
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
||
|
FDA ORPHAN DRUG |
167303
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
||
|
WHO-VATC |
QL01XX27
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
||
|
FDA ORPHAN DRUG |
167203
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
||
|
FDA ORPHAN DRUG |
109697
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
||
|
FDA ORPHAN DRUG |
201305
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
||
|
FDA ORPHAN DRUG |
135200
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
||
|
FDA ORPHAN DRUG |
134700
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
||
|
FDA ORPHAN DRUG |
645318
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/00/008
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
||
|
WHO-ATC |
L01XX27
Created by
admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB01169
Created by
admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
|
PRIMARY | |||
|
SUB25441
Created by
admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
|
PRIMARY | |||
|
12505-67-8
Created by
admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
|
ALTERNATIVE | |||
|
C006632
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | |||
|
58886963
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | |||
|
215-481-4
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | |||
|
C1005
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | |||
|
30621
Created by
admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
|
PRIMARY | |||
|
49900
Created by
admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
|
PRIMARY | |||
|
419
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | |||
|
MM-38
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | |||
|
m2065
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB12467MIG
Created by
admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
|
PRIMARY | |||
|
S7V92P67HO
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | |||
|
18330
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID0020103
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | |||
|
1327-53-3
Created by
admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
|
PRIMARY | |||
|
92859
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | |||
|
S7V92P67HO
Created by
admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
|
PRIMARY | |||
|
759274
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200978
Created by
admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
|
PRIMARY | |||
|
Arsenic Trioxide
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | |||
|
244
Created by
admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
|
PRIMARY | |||
|
ARSENIC TRIOXIDE
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY | |||
|
100000089284
Created by
admin on Fri Dec 15 15:38:30 GMT 2023 , Edited by admin on Fri Dec 15 15:38:30 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD